References
- Spitzer G., Jagannath S., Taylor K., et al. Studies of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after high dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16) (CBU therapy) with autologous bone marrow transplantation (ABMT) in relapsed Hodgkin's disease. Exp. Hematol 1989; 17: 710
- Sheridan W.P., Morstyn G., Wolf M., et al. Granulocyte colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895
- Taylor K.M., Jagannath S., Spitzer G., et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J. Clin. Oncol. 1989; 7: 1791–1799
- Gherlinzoni F., Visani G., Ricci P., et al. Hematological recovery after autologous bone marrow transplanation (ABMT) for non-Hodgkin's lymphoma: G-CSF vs GM-CSF vs no growth factors. 18th Annual Meeting of the EBMT, Stockholm 1992; 435: 211
- Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N. Engl. J. Med 1991; 325: 164–170
- Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur. J. Cancer 1993; 29A: 319–324
- Bronchud M.H., Scarffe J.H., Thatcher N., et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br. J. Cancer 1987; 56: 809–813
- Morstyn G., Campbell L., Souza L.M., et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667–671
- Gabrilove J.L., Jakubowski A., Scher H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N. Engl. J. Med. 1988; 318: 1414–1422
- Neidhart J., Mangalik A., Kobler W., et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J. Clin. Oncol. 1989; 7: 1685–1692
- Morstyn G., Campbell L., Lieschke G.J., et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol 1989; 7: 1554–1562
- Pettengell R., Gurney H., Radford J.A., et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
- Zinzani P.L., Martelli M., Tura S., et al. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma. Haematologica 1993; 78: 40–43
- Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993; 328: 1002–1006
- De Vita V.T., Jr., Hubbard S.M., Longo D.L. The chemotherapy of lymphomas: looking back, moving forward. The Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 1987; 47: 5810–5824
- De Vita V.T., Jr., Jaffe E.S., Mauch P., . Lymphocytic lymphomas. Cancer Principles and Practice of Oncology, V.T. De Vita, S. Hellman, S.A. Rosenberg, et al. JB Lippincott, Philadelphia 1989; 1741–1798
- Dixon D.O., Neilan B., Jones S.E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group Experience. J. Clin. Oncol 1986; 4: 295–305
- Falini B., Pileri S., Martelli M.F. Histological and immunohistological analysis of human lymphomas. Crit. Rev. Oncol/Hematol 1989; 9: 351–49
- Keating M.J., Kantarjan H., Talpaz M., et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
- Hryniuk W.M. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology, V.T. De Vita, S. Hellman, S.A. Rosenberg. JB Lippincott, Philadelphia 1988; 121–142
- De Vita V.T. Principles of chemotherapy. Cancer Principles and Practice of Oncology, V.T. De Vita, S. Hellman, S.A. Rosenberg. JB Lippincott, Philadelphia 1989; 276–300
- Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 1966; 64: 328–340
- O'Hanley P., Easaw J., Rugo H., et al. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am. J. Med 1989; 87: 605–613
- Klatersky J. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients. Diagn. Microbiol. Infect. Dis. 1989; 12(suppl. 4)201S
- Brown A.E. Management in the febrile, neutropenic patient with cancer, therapeutic considerations. J. Pediatr. 1985; 106: 1035–1041